Patents by Inventor Dirk Eulberg
Dirk Eulberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8691784Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115.Type: GrantFiled: June 4, 2012Date of Patent: April 8, 2014Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Publication number: 20130337049Abstract: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.Type: ApplicationFiled: July 30, 2013Publication date: December 19, 2013Applicant: NOXXON Pharma AGInventors: Axel Vater, Christian Maasch, Sven Klussmann, Werner Purschke, Dirk Eulberg, Florian Jarosch, Klaus Buchner
-
Publication number: 20130310442Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.Type: ApplicationFiled: September 9, 2011Publication date: November 21, 2013Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
-
Patent number: 8507456Abstract: The present invention is related to a nucleic acid, preferably binding to C5a, selected from the group comprising type A nucleic acids, type B nucleic acids, type C nucleic acids, type D nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 73 to 79.Type: GrantFiled: September 24, 2008Date of Patent: August 13, 2013Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Patent number: 8497250Abstract: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.Type: GrantFiled: May 4, 2006Date of Patent: July 30, 2013Assignee: NOXXON Pharma AGInventors: Axel Vater, Christian Maasch, Sven Klussmann, Werner Purschke, Dirk Eulberg, Florian Jarosch, Klaus Buchner
-
Patent number: 8383789Abstract: The present invention relates to a vasopressin-binding nucleic acid, characterized in that the nucleic acid contains a stretch Box1 and a stretch Box2, in which Box1 comprises the sequence GUGGW and W=A or U, preferably W=U, and in which Box2 comprises a sequence of about 18 to 24 nucleotides, preferably 21 nucleotides, and a group (G)n is contained four times in the sequence, in which n=2, 3 or 4.Type: GrantFiled: November 29, 2005Date of Patent: February 26, 2013Assignee: NOXXON Pharma AGInventors: Werner Purschke, Dirk Eulberg, Sven Klussmann, Ingo Rohl, Axel Vater
-
Publication number: 20130035376Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115Type: ApplicationFiled: June 4, 2012Publication date: February 7, 2013Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Patent number: 8367629Abstract: The present invention is related to a nucleic acid molecule capable of binding to MCP-1, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney disease and systemic lupus erythematosus.Type: GrantFiled: November 29, 2008Date of Patent: February 5, 2013Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Patent number: 8314223Abstract: The present invention is related to a nucleic acid molecule, preferably binding to SDF-1, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ ID NO:142, SEQ ID NO:143 or SEQ ID NO:144.Type: GrantFiled: January 18, 2009Date of Patent: November 20, 2012Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
-
Patent number: 8193159Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ. ID. No. 87 to 115.Type: GrantFiled: February 14, 2007Date of Patent: June 5, 2012Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Publication number: 20120115937Abstract: The present invention is related to a nucleic acid, preferably binding to ghrelin, whereby the nucleic acid comprises a first stretch Box A, and a second stretch Box B, whereby the first stretch Box A comprises about 25 consecutive nucleotides, the second stretch Box B comprises about six to eight consecutive nucleotides, whereby a 3?-terminal stretch of nucleotides of the first stretch Box A hybridises with the second stretch Box B, whereby upon hybridisation a first double-stranded structure is formed, whereby such first double-stranded structure comprises a bulge.Type: ApplicationFiled: January 24, 2012Publication date: May 10, 2012Applicant: NOXXON PHARMA AGInventors: Florian Jarosch, Dirk Eulberg, Christian Maasch, Steffen Helmling, Sven Klussmann
-
Publication number: 20120083520Abstract: The present invention is related to a nucleic acid antagonist of ghrelin.Type: ApplicationFiled: May 8, 2010Publication date: April 5, 2012Applicant: NOXXON PHARMA AGInventors: Steffen Helmling, Dirk Eulberg, Christian Maasch, Sven Klussmann
-
Publication number: 20120065254Abstract: The present invention is related to a nucleic acid molecule, capable of binding to C5a, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of tumors, the treatment and/or prevention of a respiratory disease, the treatment and/or prevention of pain and/or the treatment and/or prevention of a neurodegenerative disorder.Type: ApplicationFiled: March 23, 2010Publication date: March 15, 2012Applicant: NOXXON PHARMA AGInventors: Florian Jarosch, Werner Purschke, Dirk Eulberg, Christian Maasch, Klaus Buchner, Sven Klussmann
-
Patent number: 8101734Abstract: The present invention is related to a nucleic acid, preferably binding to ghrelin, whereby the nucleic acid comprises a first stretch Box A, and a second stretch Box B, whereby the first stretch Box A comprises about 25 consecutive nucleotides, the second stretch Box B comprises about six to eight consecutive nucleotides, whereby a 3?-terminal stretch of nucleotides of the first stretch Box A hybridizes with the second stretch Box B, whereby upon hybridization a first double-stranded structure is formed, whereby such first double-stranded structure comprises a bulge.Type: GrantFiled: April 7, 2006Date of Patent: January 24, 2012Assignee: NOXXON Pharma AGInventors: Florian Jarosch, Dirk Eulberg, Christian Maasch, Steffen Helmling, Sven Klussmann
-
Publication number: 20110223127Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.Type: ApplicationFiled: August 6, 2008Publication date: September 15, 2011Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
-
Publication number: 20110112172Abstract: The present invention is related to a nucleic acid molecule, preferably binding to SDF-1, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ ID NO:142, SEQ ID NO:143 or SEQ ID NO:144.Type: ApplicationFiled: January 18, 2009Publication date: May 12, 2011Applicant: NOXXON PHARMA AGInventors: WERNER PURSCHKE, FLORIAN JAROSCH, DIRK EULBERG, SVEN KLUSSMANN, KLAUS BUCHNER, CHRISTIAN MAASCH, NICOLE DINSE
-
Publication number: 20110046207Abstract: The present invention is related to a nucleic acid, preferably binding to C5a, selected from the group comprising type A nucleic acids, type B nucleic acids, type C nucleic acids, type D nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 73 to 79.Type: ApplicationFiled: September 24, 2008Publication date: February 24, 2011Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Publication number: 20100284961Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ. ID. No. 87 to 115.Type: ApplicationFiled: February 14, 2007Publication date: November 11, 2010Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Publication number: 20100261291Abstract: The present invention is related to a nucleic acid specifically binding bioactive ghrelin, more preferably n-octanoyl ghrelin, and its use for the diagnosis of ghrelin mediated diseases and disorders.Type: ApplicationFiled: February 24, 2010Publication date: October 14, 2010Applicant: NOXXON Pharma AGInventors: SVEN KLUSSMANN, STEFFEN HELMLING, DIRK EULBERG, CHRISTIAN MAASCH, KLAUS BUCHNER
-
Patent number: 7750140Abstract: The present invention is related to an antagonist of ghrelin, wherein the antagonist is a nucleic acid, and whereby preferably the nucleic acid is binding to ghrelin.Type: GrantFiled: August 1, 2003Date of Patent: July 6, 2010Assignee: NOXXON Pharma AGInventors: Steffen Helmling, Dirk Eulberg, Christian Maasch, Sven Klussmann